New hope for leprosy patients: experimental drug dovramilast under trial
NCT ID NCT07172659
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called dovramilast in 45 adults with moderate to severe leprosy type 2 reaction, a painful skin condition. Participants receive either dovramilast (100 mg or 150 mg) or standard treatments like prednisolone or thalidomide. The goal is to see if dovramilast can reduce skin lesions by 75% in 12 weeks and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dovramilast
What this could lead to
If successful, dovramilast could offer a new treatment option for leprosy type 2 reaction, potentially reducing reliance on current therapies like steroids or thalidomide.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 45 participants. The drug is unapproved anywhere, and its safety and effectiveness are not yet proven. It may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHEMA NODOSUM LEPROSUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli
NOT_YET_RECRUITINGAbomey-Calavi, Benin
-
Chr de Divo
NOT_YET_RECRUITINGDivo, Côte d’Ivoire
-
Harborview Medical Center, University of Washington
NOT_YET_RECRUITINGSeattle, Washington, 98104, United States
-
Philippine General Hospital, University of the Philippines, Manila
RECRUITINGManila, Philippines
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Programme national lutte contre la lèpre
NOT_YET_RECRUITINGTôlanaro, Madagascar
Contact Email: •••••@•••••
-
Universitas Gadjah Mada
NOT_YET_RECRUITINGYogyakarta, Indonesia